about
Prevention of HIV-1 infection with early antiretroviral therapyAbacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensCurrent strategies to treat tuberculosisClinical research and development of tuberculosis diagnostics: moving from silos to synergyBaseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialClinical evaluation of a dried blood spot assay for atazanavirVirologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.Abnormal MEG oscillatory activity during visual processing in the prefrontal cortices and frontal eye-fields of the aging HIV brain.HIV-1-associated dementia: a basic science and clinical perspective.Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study.The critical need for alternative antiretroviral formulations, and obstacles to their development.CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal modelMultimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adults.Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.New drugs to treat tuberculosis.A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries.Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionModeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamideThe F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialEvaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence SettingsClinical utility of interferon gamma assay in the diagnosis of tuberculosis.Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionRelationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA.Controlling healthcare-associated infections in the international research setting.Functional brain abnormalities during finger-tapping in HIV-infected older adults: a magnetoencephalography studySimplification strategies to reduce antiretroviral drug exposure: progress and prospects.Extensively drug-resistant tuberculosis.Antiretroviral Therapy for the Prevention of HIV-1 TransmissionClass-sparing regimens for initial treatment of HIV-1 infection.Decreased MEG beta oscillations in HIV-infected older adults during the resting state.Pilot study of younger and older HIV-infected adults using traditional and novel functional assessments.
P50
Q24634688-D71AB500-F041-48FD-B139-322013391F58Q24799351-6FBFEDDE-5A98-414C-A8E0-B2D74CC60CC1Q28075252-B82CBEED-8C7D-4015-80C2-5B4596CCAF98Q28383710-C04532D2-8C9E-45D2-82A4-D535A9832A4FQ33572705-9FC2D6C7-4928-401B-8C79-0CC9CDC54E42Q33968358-C088C202-EE60-4194-BDA7-63835F1A6F3EQ34086963-A4D24A0C-1052-4884-88DC-8B341F60213DQ34150893-56380453-5011-4069-9092-1501BAEC91D8Q34400849-D07EF75B-C6BD-4790-A979-05526A263B13Q34805196-211E213E-31FA-4280-BFC3-BE31616FD751Q34851319-5EAC0412-52BD-4F09-916A-75D8F87D5ADBQ34979146-55EC7708-9F90-4E99-979E-0BA619BA9582Q35164438-284F17D5-7EE1-4609-BAC9-8C0581331BB5Q35528462-CEF0B34B-4C5D-45A7-9465-7E8A5859CD57Q35570991-55A2050B-9F5F-4768-9295-014B9DE282B6Q35819368-5ECE9112-4B8B-475D-A502-E8047F4D493CQ35827839-FE876357-AABA-45D3-8904-370EEF35C68DQ35872395-203B8C51-C38E-4B63-A283-169021BFF04BQ35890799-38372974-EC89-40EB-B777-DD71CF4F3243Q36018409-B0C44F92-30A6-45FF-8262-A9B9EDCF1DC5Q36048933-D2D00F2A-3384-4626-8680-EBCAE70CAE6CQ36094233-25978B6D-5EFE-4904-9B27-5C4237968897Q36236341-CA176CE2-40AD-4250-9A21-8F6EEC25C073Q36580911-BC4E41C5-C70A-4865-B984-555B57C16655Q36603756-3139A0AC-DE99-426C-96D5-D29E7BC06CAEQ36627942-86AB00A1-B50F-4D9B-84D9-3D3D85C2C721Q36783193-E6A35F3E-67E1-449D-9C1C-E47BD39B0D50Q36978740-05BCA1CA-6ABB-4C20-ADD1-A50DA1CB6AECQ37014157-4D937306-574E-4EB2-B7EA-1AB8AD906E23Q37036991-FFAF38A3-6641-4471-92DB-9C09F22C5E77Q37189025-8BA0679E-051B-4A81-8638-02BFAB34D64BQ37198065-D75656BC-69DD-4B91-91E2-04127B412C5EQ37241428-D7209CF3-A469-4279-8705-C4ACAD5B63FCQ37257522-C8E303BA-044A-47E4-A922-6E96F38C0E69Q37277829-98EB2E4E-0A19-440A-A134-BC38E7A90EBAQ37281779-F5A74EFE-C0E7-40AA-8368-C509AF76D947Q37308674-2BCB843E-8FEE-4BAA-BA90-D6E07350560CQ37454026-8690302E-AB74-4B5A-8032-256015FD18F2Q37552824-F3E84761-4F11-4061-A53E-01DF4F441BC4Q37597286-D73DADB3-09E0-41D3-A0DF-AB82798BD2C9
P50
name
Susan Swindells
@en
Susan Swindells
@nl
type
label
Susan Swindells
@en
Susan Swindells
@nl
prefLabel
Susan Swindells
@en
Susan Swindells
@nl